1. Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever
- Author
-
Esragül Akinci, Mustafa Sunbul, Hakan Leblebicioglu, and Hurrem Bodur
- Subjects
0301 basic medicine ,Crimean–Congo hemorrhagic fever ,medicine.medical_specialty ,030106 microbiology ,Clinical Decision-Making ,Disease ,Severity of Illness Index ,03 medical and health sciences ,Virology ,Intensive care ,Severity of illness ,Epidemiology ,Health care ,Medicine ,Humans ,Genetic Predisposition to Disease ,Disease management (health) ,Intensive care medicine ,Pharmacology ,business.industry ,Mortality rate ,Disease Management ,Viral Load ,medicine.disease ,Prognosis ,Hemorrhagic Fever Virus, Crimean-Congo ,Hemorrhagic Fever, Crimean ,Symptom Assessment ,business ,Biomarkers - Abstract
Crimean-Congo hemorrhagic fever (CCHF) is a geographically widespread tick-borne zoonosis. The clinical spectrum of the illness varies from mild infection to severe disease and death. In severe cases, hemorrhagic manifestations develop, with fatality rates of 4-20%, depending on the geographic region and quality of the health care. Although vast majority of the CCHF cases were reported from Turkey, mortality rate is lower than the other regions, which is 5% on average. Prediction of the clinical course of the disease enables appropriate management planning by the physician and prompt transportation, if needed, of the patient to a tertiary care hospital for an intensive therapy. Thus, predicting the outcome of the disease may avert potential mortality. There are numerous studies investigating the prognostic factors of CCHF in the literature. Majority of them were reported from Turkey and included investigations on clinical and biochemical parameters, severity scoring systems and some novel biomarkers. Somnolence, bleeding, thrombocytopenia, elevated liver enzymes and prolonged bleeding times are the most frequently reported prognostic factors to predict the clinical course of the disease earlier. High viral load seems to be the strongest predictor to make a clinical decision about the patient outcome. The severity scoring systems based on clinically important mortality-related parameters are especially useful for clinicians working in the field to predict the course of the disease and to decide which patient should be referred to a tertiary care hospital for intensive care. In the light of the pathophysiological characteristics of CCHF, some new biomarkers of prognosis including cytokines, soluble adhesion molecules, genetic polymorphisms and coagulopathy parameters were also investigated. However most of these tests are not available to clinicians and they were obtained mostly for research purposes. In spite of the various studies about prognostic factors, they have several inherent limitations, including large variability in the results and confusing data that are not useful for clinicians in routine practice. In this paper, the results of diverse studies of the prediction of the prognosis in CCHF based on epidemiological, clinical and laboratory findings of the disease were summarized and suggestions for future studies are provided.
- Published
- 2016